FDA Grants Expanded Use of Pfizer Cancer Drug Xalkori

The Wall Street Journal (online registration required): The U.S. Food and Drug Administration on Friday approved Pfizer Inc.’s Xalkori for treatment of a rare form of advanced non-small-cell lung cancer, making it the first therapy for the condition.

The drug’s use has been expanded to treat the roughly 1% of patients with advanced, or metastatic, non-small cell lung cancer whose tumors have an ROS-1 gene alteration, thought to lead to abnormal cells. Xalkori, or crizotinib, is the first..

Read article